

Monoamine Oxidase Inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/M6BDD9AAB9CEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: M6BDD9AAB9CEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Monoamine Oxidase Inhibitor (MAOIs) - Pipeline Insight, 2022" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitor (MAOIs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Monoamine Oxidase Inhibitor (MAOIs) Understanding

Monoamine Oxidase Inhibitor (MAOIs): Overview

Monoamine oxidase (MAO; EC 1.4.3.4.) is a widely distributed mitochondrial enzyme with high expression levels in gastro-intestinal and hepatic as well as neuronal tissues. There are two types of monoamine oxidase, A and B. The MOA A is mostly distributed in the placenta, gut, and liver, but MOA B is present in the brain, liver, and platelets.

Function - The enzyme catalyzes the oxidative deamination of a variety of monoamines, both endogenous and exogenous, and has major roles in metabolizing released neurotransmitters, and in detoxification of a large variety of endogenous and exogenous amines.

Monoamine Oxidase Inhibitor (MAOIs) - Monoamine Oxidase Inhibitor (MAOIs) are responsible for blocking the monoamine oxidase enzyme. The monoamine oxidase enzyme breaks down different types of neurotransmitters from the brain: norepinephrine, serotonin, dopamine, and tyramine. MAOIs inhibit the breakdown of these neurotransmitters thus, increasing their levels and allowing them to continue to influence the cells that have been affected by depression.

Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs Chapters

This segment of the Monoamine Oxidase Inhibitor (MAOIs) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs

Ladostigil: Avraham Pharmaceuticals

Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.

Safinamide: Newron Pharmaceuticals

A selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of secreted dopamine, helping to maintain the density of dopamine in the brain. The drug is in phase 2 stage of development for the treatment of Drug-induced dyskinesia.

Further product details are provided in the report.....

Monoamine Oxidase Inhibitor (MAOIs): Therapeutic Assessment

This segment of the report provides insights about the different Monoamine Oxidase Inhibitor (MAOIs) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Monoamine Oxidase Inhibitor (MAOIs)

There are approx. 7+ key companies which are developing the Monoamine Oxidase Inhibitor (MAOIs). The companies which have their Monoamine Oxidase Inhibitor (MAOIs) drug candidates in the most advanced stage, i.e. preregistration include, Amgen.

Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Monoamine Oxidase Inhibitor (MAOIs) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Monoamine Oxidase Inhibitor (MAOIs): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Monoamine Oxidase Inhibitor (MAOIs) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Monoamine Oxidase Inhibitor (MAOIs) drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Monoamine Oxidase Inhibitor (MAOIs) R&D. The therapies under development are focused on novel approaches for Monoamine Oxidase Inhibitor (MAOIs).

Monoamine Oxidase Inhibitor (MAOIs) Report Insights

Monoamine Oxidase Inhibitor (MAOIs) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Monoamine Oxidase Inhibitor (MAOIs) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Monoamine Oxidase Inhibitor (MAOIs) drugs?

How many Monoamine Oxidase Inhibitor (MAOIs) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Monoamine Oxidase Inhibitor (MAOIs)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Monoamine Oxidase Inhibitor (MAOIs) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Monoamine Oxidase Inhibitor (MAOIs) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Avraham Pharmaceuticals

PREXA SANTE

Newron Pharmaceuticals

Oryzon Genomics

Ipsen

Provepharm

Roche

Changzhou Si Yao Pharmaceutical

Key Products

Ladostigil

Methylthioninium chloride

Safinamide

Vafidemstat

BN 82451

ProvayBlue

Sembragiline

Rasagiline

Contents

Introduction

Executive Summary

Monoamine Oxidase Inhibitor (MAOIs): Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Monoamine Oxidase Inhibitor (MAOIs) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Monoamine Oxidase Inhibitor (MAOIs) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Monoamine Oxidase Inhibitor (MAOIs) Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Safinamide: Newron Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Rasagiline: Changzhou Si Yao Pharmaceutical

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Monoamine Oxidase Inhibitor (MAOIs) Key Companies

Monoamine Oxidase Inhibitor (MAOIs) Key Products

Monoamine Oxidase Inhibitor (MAOIs)- Unmet Needs

Monoamine Oxidase Inhibitor (MAOIs)- Market Drivers and Barriers

Monoamine Oxidase Inhibitor (MAOIs)- Future Perspectives and Conclusion

Monoamine Oxidase Inhibitor (MAOIs) Analyst Views

Monoamine Oxidase Inhibitor (MAOIs) Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Monoamine Oxidase Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Monoamine Oxidase Inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Monoamine Oxidase Inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/M6BDD9AAB9CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6BDD9AAB9CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970